Anika Therapeutics (ANIK) vs Embecta (EMBC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed Embecta (EMBC) over the past year, gaining 114.9% versus a loss of 57.1%. Embecta is the larger company by market cap ($334.9 million vs $261.4 million), about 1.3 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 20.6x for Anika Therapeutics).
Embecta pays a dividend yielding 7.78%, while Anika Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | EMBC |
|---|---|---|
| Share price | $19.53 | $5.91 |
| Market cap | $261.37M | $334.86M |
| 1-day change | +2.14% | -0.67% |
| YTD return | +103.23% | -50.25% |
| 1-year return | +114.85% | -57.11% |
| 5-year return | -53.12% | — |
| P/E ratio (TTM) | — | 4.02 |
| Forward P/E | 20.56 | 3.35 |
| EPS (TTM) | $-0.23 | $1.47 |
| Dividend yield | 0.00% | 7.78% |
| Annual dividend | $0.00 | $0.46 |
| 52-week high | $22.88 | $14.91 |
| 52-week low | $8.67 | $2.77 |
| Distance from 52-week high | -14.64% | -60.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +17.77% | -32.32% |
| Average volume | 98.57K | 1.37M |
| Shares outstanding | 13.38M | 56.66M |
| Employees | 235 | 1,850 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed EMBC by 172.0 percentage points over the past year.
- Embecta offers a meaningfully higher dividend yield (7.78% vs 0.00%).
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
ANIK vs EMBC FAQ
Which is bigger, Anika Therapeutics or Embecta?
Embecta (EMBC) is larger, with a market capitalization of $334.86M compared with $261.37M for Anika Therapeutics (ANIK).
Which stock has performed better over the past year, ANIK or EMBC?
ANIK returned +114.85% over the past 12 months, compared with -57.11% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Anika Therapeutics or Embecta?
Embecta pays a dividend yielding 7.78%, while Anika Therapeutics does not currently pay a regular dividend.
Are Anika Therapeutics and Embecta in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.